Health Care·Biotechnology·$24.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.67 | N/A | -35.15% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $2.67 | N/A | -35.15% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concern over the lower-than-expected EPS. They did not provide any updates on future guidance.
Management acknowledged the unexpected EPS decline.
No specific guidance was provided for future performance.
The earnings report indicates that United Therapeutics faced challenges in meeting earnings expectations, which resulted in a stock decline of 4.51%. The lack of revenue data and guidance may contribute to uncertainty among investors. Overall, the market reacted negatively due to the significant EPS miss.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PHOTRONICS INC
Feb 20, 2023